Andere talen Aprea Therapeutics, Inc.

Aandelen

APRE

US03836J2015

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,07 ^USD	-0,49%		+1,50%	-13,40%

24/06	Transcript : Aprea Therapeutics, Inc. - Special Call
17/06	Aprea Therapeutics kondigt aan dat de eerste patiënt gediagnosticeerd is in de ACESOT-1051 Fase 1 studie waarbij de orale WEE1-remmer APR-1051 wordt geëvalueerd	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024	21/06
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051	17/06
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051	17/06
Aprea Therapeutics Announces that Safety Review Committee Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical trial	29/05
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial	28/05
Aprea Therapeutics, Inc. Announces Safety Review Committee Endorses Dosing of Patients with ATRN-119 at 800 Mg Once Daily in Ongoing ABOYA-119 Clinical Trial	28/05
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update	14/05
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference	13/05
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	02/05
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza as Chief Medical Officer	02/05
Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	10/04
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024	10/04
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	26/03
Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	26/03
Aprea Therapeutics Receives FDA Approval of the IND Application for the Drug Candidate Apr-1051	14/03
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million	11/03
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers	11/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aprea Therapeutics, Inc.

Aandelen

APRE

US03836J2015

Andere talen

Filters